Antibody-drug conjugates: beyond current approvals and potential future strategies.
Antibody-drug conjugates
immunotherapy
tumour microenvironment
Journal
Exploration of targeted anti-tumor therapy
ISSN: 2692-3114
Titre abrégé: Explor Target Antitumor Ther
Pays: United States
ID NLM: 101770662
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
11
2021
accepted:
07
02
2022
entrez:
1
9
2022
pubmed:
2
9
2022
medline:
2
9
2022
Statut:
ppublish
Résumé
The recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in recent years have fuelled the ongoing development of this class of drugs. These novel agents combine the benefits of high specific targeting of oncogenic cell surface antigens with the additional cell kill from high potency cytotoxic payloads, thus achieving wider therapeutic windows. This review will summarise the clinical activity of ADCs in tumour types not covered elsewhere in this issue, such as gastrointestinal (GI) and genitourinary (GU) cancers and glioblastoma (GBM). In addition to the ongoing clinical testing of existing ADCs, there is substantial preclinical and early phase testing of newer ADCs or ADC incorporating strategies. This review will provide selected insights into such future development, focusing on the development of novel ADCs against new antigen targets in the tumour microenvironment (TME) and combination of ADCs with immuno-oncology (IO) agents.
Identifiants
pubmed: 36046842
doi: 10.37349/etat.2022.00082
pii: etat-03-100282
pmc: PMC9400743
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
252-277Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Am J Transl Res. 2020 Jul 15;12(7):3557-3576
pubmed: 32774719
Nat Genet. 2012 Jul 01;44(8):852-60
pubmed: 22751098
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Oncol Rep. 2021 Jan;45(1):329-336
pubmed: 33200231
Mol Cancer Ther. 2021 Aug;20(8):1442-1453
pubmed: 34045233
Molecules. 2020 Oct 16;25(20):
pubmed: 33081383
MAbs. 2014 Jan-Feb;6(1):15-7
pubmed: 24423577
Lancet Oncol. 2020 Oct;21(10):1283-1295
pubmed: 33002436
ESMO Open. 2020 Sep;5(5):e000911
pubmed: 32988996
Lancet Oncol. 2017 May;18(5):640-653
pubmed: 28343975
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
N Engl J Med. 2021 Mar 4;384(9):829-841
pubmed: 33657295
Cancer Res. 2018 Feb 1;78(3):758-768
pubmed: 29217763
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
Lancet Oncol. 2021 May;22(5):609-619
pubmed: 33845034
Neuro Oncol. 2020 May 15;22(5):684-693
pubmed: 31747009
MAbs. 2019 Aug/Sep;11(6):987-995
pubmed: 31208270
Cancer Discov. 2022 Jan;12(1):74-89
pubmed: 34548309
Mol Cancer Ther. 2018 Jul;17(7):1494-1503
pubmed: 29703841
Trials. 2013 Aug 19;14:261
pubmed: 23958221
Clin Cancer Res. 2014 Sep 1;20(17):4436-41
pubmed: 24879797
Invest New Drugs. 2020 Dec;38(6):1807-1814
pubmed: 32472319
Cancers (Basel). 2019 Mar 20;11(3):
pubmed: 30897808
Gastric Cancer. 2021 Jul;24(4):913-925
pubmed: 33945049
Leuk Res. 2016 Nov;50:123-131
pubmed: 27736729
Int J Cancer. 2017 Oct 15;141(8):1682-1689
pubmed: 28677116
Nat Rev Clin Oncol. 2021 Aug;18(8):506-525
pubmed: 33864051
Oncogene. 2013 Mar 21;32(12):1594-600
pubmed: 22562244
N Engl J Med. 2008 Oct 23;359(17):1757-65
pubmed: 18946061
JAMA. 2010 May 5;303(17):1753-4
pubmed: 20442394
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Mol Cancer Ther. 2017 Apr;16(4):681-693
pubmed: 28108597
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Int J Cancer. 2002 Dec 10;102(5):514-8
pubmed: 12432555
Cancers (Basel). 2018 Dec 17;10(12):
pubmed: 30562956
Front Oncol. 2021 Jul 28;11:628677
pubmed: 34395236
Biomed Pharmacother. 2020 May;125:110009
pubmed: 32106381
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Cell. 2017 Dec 14;171(7):1678-1691.e13
pubmed: 29245013
J Clin Oncol. 2017 Oct 10;35(29):3338-3346
pubmed: 28817371
Cancer Res. 2018 Jul 15;78(14):4059-4072
pubmed: 29764866
MAbs. 2021 Jan-Dec;13(1):1951427
pubmed: 34291723
Clin Cancer Res. 2016 Apr 15;22(8):1989-99
pubmed: 26589436
J Hematol Oncol. 2020 Aug 18;13(1):114
pubmed: 32811512
FEBS J. 2013 Nov;280(21):5350-70
pubmed: 23777544
Int J Mol Sci. 2021 Apr 30;22(9):
pubmed: 33946310
Cancer Sci. 2016 Jul;107(7):1039-46
pubmed: 27166974
Nat Med. 2018 Feb;24(2):203-212
pubmed: 29334371
Front Cell Dev Biol. 2021 Oct 29;9:752426
pubmed: 34778263
Curr Neurol Neurosci Rep. 2020 May 22;20(7):19
pubmed: 32445058
Clin Transl Oncol. 2022 Mar;24(3):568-577
pubmed: 34687441
Ann Transl Med. 2021 Jul;9(14):1113
pubmed: 34430554
Cancer Cell. 2016 Jan 11;29(1):117-29
pubmed: 26766593
Lancet. 2014 Jan 4;383(9911):31-39
pubmed: 24094768
Cancer Manag Res. 2021 Apr 09;13:3113-3122
pubmed: 33859497
Sci Transl Med. 2015 Nov 25;7(315):315ra188
pubmed: 26606967
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
Lancet Oncol. 2016 Jun;17(6):738-746
pubmed: 27108243
Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217
pubmed: 29075855
Nat Rev Drug Discov. 2016 Feb;15(2):81-2
pubmed: 26837588
N Engl J Med. 2021 Mar 25;384(12):1125-1135
pubmed: 33577729
Eur J Med Chem. 2017 Dec 15;142:393-415
pubmed: 28911823
Cancer Cell. 2003 Mar;3(3):207-12
pubmed: 12676579
Cells. 2021 Jan 01;10(1):
pubmed: 33401460
Ther Adv Med Oncol. 2021 Oct 26;13:17588359211053898
pubmed: 34721674
Nat Rev Immunol. 2015 Nov;15(11):669-82
pubmed: 26471778
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Am J Clin Exp Urol. 2021 Feb 15;9(1):73-87
pubmed: 33816696
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Br J Cancer. 2000 Jul;83(2):164-70
pubmed: 10901365
Cancer Cell. 2013 Feb 11;23(2):238-48
pubmed: 23410976
Oncol Rev. 2021 Feb 26;15(1):530
pubmed: 33747368
Front Immunol. 2020 Jul 17;11:1402
pubmed: 32765498
Cancer Lett. 2020 Feb 1;470:126-133
pubmed: 31730903
Cancer Res. 2014 Aug 15;74(16):4470-81
pubmed: 25125683
J Clin Invest. 2018 Jul 2;128(7):2927-2943
pubmed: 29863500
Clin Cancer Res. 2021 Feb 15;27(4):922-927
pubmed: 32962979
Lancet Oncol. 2017 Oct;18(10):e563
pubmed: 28844817
Nat Commun. 2021 Jul 20;12(1):4413
pubmed: 34285210
N Engl J Med. 2022 Jan 20;386(3):241-251
pubmed: 34534430
Expert Rev Anticancer Ther. 2021 Apr;21(4):401-412
pubmed: 33287612
Angew Chem Int Ed Engl. 2014 Apr 7;53(15):3796-827
pubmed: 24677743
Br J Cancer. 2020 Mar;122(5):603-612
pubmed: 31839676
J Clin Oncol. 2020 Apr 1;38(10):1041-1049
pubmed: 32031899
Prostate. 2019 May;79(6):604-613
pubmed: 30663074
JCO Oncol Pract. 2022 Mar;18(3):187-196
pubmed: 34529499
Thromb Res. 2012 Apr;129 Suppl 1:S46-9
pubmed: 22682132
Int J Mol Sci. 2019 Mar 05;20(5):
pubmed: 30841523
Cancer J. 2008 May-Jun;14(3):154-69
pubmed: 18536555
J Clin Oncol. 2019 Dec 20;37(36):3518-3527
pubmed: 31689155
CA Cancer J Clin. 2022 Mar;72(2):165-182
pubmed: 34767258
Cancer Res. 2004 Aug 1;64(15):5471-80
pubmed: 15289357
Protein Cell. 2018 Jan;9(1):33-46
pubmed: 27743348
Clin Breast Cancer. 2021 Dec;21(6):539-551
pubmed: 34154926
Prostate. 2020 Jan;80(1):99-108
pubmed: 31742767
Science. 1970 Jul 3;169(3940):68-70
pubmed: 4986716
Mol Cancer Ther. 2018 Oct;17(10):2176-2186
pubmed: 30065100
Neuro Oncol. 2016 Jul;18(7):914-8
pubmed: 26755074
Neuro Oncol. 2019 Jan 1;21(1):106-114
pubmed: 29982805
Lancet Oncol. 2017 Jun;18(6):743-754
pubmed: 28526538
Nat Commun. 2014 Dec 15;5:5712
pubmed: 25502142
Adv Drug Deliv Rev. 1998 Apr 6;31(1-2):89-104
pubmed: 10837619
Expert Opin Biol Ther. 2020 Mar;20(3):253-262
pubmed: 31914333
Neuro Oncol. 2020 Aug 17;22(8):1073-1113
pubmed: 32328653
Tumour Biol. 2016 Sep;37(9):11959-11971
pubmed: 27101199
Lancet Oncol. 2019 Apr;20(4):518-530
pubmed: 30857956
Mol Pharm. 2020 Sep 8;17(9):3392-3402
pubmed: 32803984
Front Biosci (Landmark Ed). 2018 Jun 1;23(10):1933-1968
pubmed: 29772538
Cancer Chemother Pharmacol. 2019 Aug;84(2):327-336
pubmed: 31154523
J Clin Oncol. 2021 Aug 1;39(22):2474-2485
pubmed: 33929895
Lancet Oncol. 2021 Jun;22(6):872-882
pubmed: 33991512
Prostate Cancer Prostatic Dis. 2021 Jun;24(2):301-309
pubmed: 33168966
Lancet Oncol. 2021 Jun;22(6):779-789
pubmed: 33961795
BMC Cancer. 2007 Jan 03;7:2
pubmed: 17201906
Pharmacol Ther. 2022 Aug;236:108106
pubmed: 34990642
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
Front Oncol. 2021 Apr 23;11:638482
pubmed: 33968735
J Cell Biochem. 2007 Jul 1;101(4):805-15
pubmed: 17226777
Clin Cancer Res. 2012 Aug 15;18(16):4266-76
pubmed: 22896693
Anticancer Res. 1999 Mar-Apr;19(2C):1541-3
pubmed: 10365141
Immunotargets Ther. 2021 Aug 05;10:313-323
pubmed: 34386436
N Engl J Med. 2021 Apr 1;384(13):1191-1203
pubmed: 33789008
Clin Cancer Res. 2009 Oct 1;15(19):6052-61
pubmed: 19789330
Clin Cancer Res. 2021 Jul 1;27(13):3556-3566
pubmed: 33820780
Mol Cancer Ther. 2016 Nov;15(11):2688-2697
pubmed: 27559142
J Clin Invest. 2020 Jan 2;130(1):374-388
pubmed: 31661465
Ann Oncol. 2020 Mar;31(3):430-434
pubmed: 32067685
Clin Cancer Res. 2021 Jul 1;27(13):3602-3609
pubmed: 33795255
Clin Cancer Res. 2020 Jul 1;26(13):3420-3430
pubmed: 32161121
Mol Cancer Ther. 2015 Jul;14(7):1614-24
pubmed: 25931519
Oncotarget. 2016 Sep 13;7(37):59860-59876
pubmed: 27494882
Cancer Res. 2016 May 15;76(10):3003-13
pubmed: 27013195
Nat Rev Clin Oncol. 2021 Jun;18(6):327-344
pubmed: 33558752
Cancer Res. 2012 May 15;72(10):2473-80
pubmed: 22414581
Breast Cancer Res Treat. 2015 Aug;153(1):123-33
pubmed: 26253944
N Engl J Med. 2014 Oct 23;371(17):1609-18
pubmed: 25337750
Mol Biol Rep. 2020 Jul;47(7):5523-5533
pubmed: 32621117
Expert Rev Anticancer Ther. 2020 Jul;20(7):551-561
pubmed: 32552213
Drugs. 2020 Jan;80(1):1-7
pubmed: 31823332
Expert Rev Respir Med. 2020 Feb;14(2):137-147
pubmed: 31815565
Cancer Res. 2017 May 15;77(10):2686-2698
pubmed: 28283653
Breast Cancer Res. 2014 Mar 05;16(2):209
pubmed: 24887180
Mol Cancer Ther. 2015 May;14(5):1141-51
pubmed: 25731184
JAMA Oncol. 2021 Dec 01;7(12):1873-1881
pubmed: 34647966
Breast Cancer Res Treat. 2022 Jan;191(1):51-61
pubmed: 34657203
Ann Oncol. 2015 Jan;26(1):7-9
pubmed: 25361990
Trends Cancer. 2020 Jul;6(7):605-618
pubmed: 32610070
Clin Cancer Res. 2021 Jan 1;27(1):43-51
pubmed: 33109737
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197
J Clin Oncol. 2019 Oct 10;37(29):2592-2600
pubmed: 31356140
Nat Rev Clin Oncol. 2014 Nov;11(11):637-48
pubmed: 25265912
Ann Oncol. 2018 May 1;29(5):1108-1119
pubmed: 29659677
J Gastroenterol. 2012 Jul;47(7):785-94
pubmed: 22350700
MAbs. 2013 Jan-Feb;5(1):13-21
pubmed: 23221464
Annu Rev Med. 2018 Jan 29;69:191-207
pubmed: 29414262
Oncologist. 2021 Mar;26(3):182-e361
pubmed: 33289953
Clin Cancer Res. 2003 May;9(5):1639-47
pubmed: 12738716
N Engl J Med. 2020 Jun 18;382(25):2419-2430
pubmed: 32469182
Nat Rev Clin Oncol. 2017 Nov;14(11):695-707
pubmed: 28675164
Lancet. 2021 Jul 3;398(10294):27-40
pubmed: 34102137
Cancer Sci. 2019 Oct;110(10):3296-3305
pubmed: 31348600
J Neurooncol. 2021 Apr;152(2):233-243
pubmed: 33517558
World J Gastrointest Oncol. 2021 May 15;13(5):366-390
pubmed: 34040699
Cancer. 2018 Apr 1;124(7):1358-1373
pubmed: 29338072
Drug Discov Today Technol. 2018 Dec;30:55-61
pubmed: 30553521